Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Radboud University
• Collaborator: Pfizer
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Male

• Age 18-50 years

• Informed consent

• Physical able to perform ischemic exercise

Exclusion Criteria:

• History of any cardiovascular disease

• Hypertension (in supine position: systole > 140 mmHg, diastole > 90 mmHg)

• Diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)

• Hyperlipidaemia (fasting total cholesterol > 5.5 mmol/l)

• Alanine-Amino-Transferase (ALAT) >90 U/L

• Creatinine Kinase (CK) >440 U/L

• Drug or alcohol abuse

• Concommitant chronic use of medication

• Administration of radioactivity in research setting during the last 5 years

• Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures